Perceptive Advisors LLC reported 92 positions worth $6.02B for the quarter ended Jun 30, 2026, up 35.2% on the prior quarter. It opened 19 new positions, added to 29, trimmed 26 and exited 7. Its largest holding is Praxis Precision Medicines, Inc. at 11.3% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| KARD Kardigan, Inc. | +8.20M | – | $195.59M | 3.25% |
| AVLN Avalyn Pharma Inc. | +2.68M | – | $88.07M | 1.46% |
| RLAY Relay Therapeutics, Inc. | +4.36M | +44.7% | $81.48M | 4.38% |
| TNGX Tango Therapeutics, Inc. | +2.57M | +317.9% | $80.30M | 1.75% |
| BIIB Biogen Inc. | +276.2K | – | $59.67M | 0.991% |
| RVMD Revolution Medicines, Inc. | +269.0K | +104.0% | $50.38M | 1.64% |
| UNH Unitedhealth Group Inc | +116.8K | – | $48.55M | 0.806% |
| SYRE Spyre Therapeutics, Inc. | +536.3K | +14.2% | $47.61M | 6.37% |
| CRL Charles River Laboratories International, Inc. | +140.0K | – | $31.75M | 0.527% |
| CORT Corcept Therapeutics Inc | +348.4K | +696.8% | $30.29M | 0.575% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| ASND Ascendis Pharma A/S | -367.7K | -24.0% | $98.07M | 5.15% |
| DYN Dyne Therapeutics, Inc. | -1.98M | -42.4% | $43.97M | 0.992% |
| GH Guardant Health, Inc. | -258.7K | -86.2% | $38.81M | 0.103% |
| PTGX Protagonist Therapeutics, Inc | -249.0K | -20.2% | $30.52M | 2% |
| DRUG Bright Minds Biosciences Inc. | -377.5K | -100.0% | $27.55M | Exited |
| BLTE Belite Bio, Inc | -152.0K | -100.0% | $24.23M | Exited |
| TVTX Travere Therapeutics, Inc. | -390.0K | -9.4% | $22.15M | 3.54% |
| AXGN Axogen, Inc. | -450.0K | -64.5% | $20.79M | 0.19% |
| INBX Inhibrx Biosciences, Inc. | -144.9K | -10.0% | $13.73M | 2.04% |
| ISRG Intuitive Surgical Inc | -33.5K | -39.3% | $13.34M | 0.343% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| KARD Kardigan, Inc. | +8.20M | $195.59M | 3.25% |
| AVLN Avalyn Pharma Inc. | +2.68M | $88.07M | 1.46% |
| BIIB Biogen Inc. | +276.2K | $59.67M | 0.991% |
| UNH Unitedhealth Group Inc | +116.8K | $48.55M | 0.806% |
| CRL Charles River Laboratories International, Inc. | +140.0K | $31.75M | 0.527% |
| DHR Danaher Corp | +130.0K | $24.76M | 0.411% |
| ANL Adlai Nortye Group Ltd. | +1.79M | $20.62M | 0.342% |
| NVCT Nuvectis Pharma, Inc. | +1.00M | $18.39M | 0.305% |
| MIRM Mirum Pharmaceuticals, Inc. | +115.4K | $13.51M | 0.224% |
| OSCR Oscar Health, Inc. | +400.0K | $11.41M | 0.189% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| DRUG Bright Minds Biosciences Inc. | -377.5K | $27.55M | 0.619% |
| BLTE Belite Bio, Inc | -152.0K | $24.23M | 0.544% |
| EVMN Evommune, Inc. | -448.4K | $10.31M | 0.231% |
| NMRA Neumora Therapeutics, Inc. | -5.10M | $9.95M | 0.223% |
| NBIX Neurocrine Biosciences Inc | -65.1K | $8.57M | 0.192% |
| IRD Opus Genetics, Inc. | -1.84M | $8.35M | 0.188% |
| IKT Inhibikase Therapeutics, Inc. | -2.32M | $3.89M | 0.087% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | PRAX Praxis Precision Medicines, Inc. | Healthcare | 2.04M | $681.63M | 11.32% | 0 | 0.0% | Unchanged | 6.99% |
| 2 | SYRE Spyre Therapeutics, Inc. | Healthcare | 4.32M | $383.48M | 6.37% | +536.3K | +14.2% | Added | 5.1% |
| 3 | CELC Celcuity Inc. | Healthcare | 3.20M | $334.49M | 5.56% | +70.0K | +2.2% | Added | 5.83% |
| 4 | ASND Ascendis Pharma A/S | Healthcare | 1.16M | $310.39M | 5.15% | -367.7K | -24.0% | Reduced | 1.92% |
| 5 | RYTM Rhythm Pharmaceuticals, Inc. | Healthcare | 2.59M | $287.16M | 4.77% | +212.5K | +9.0% | Added | 3.76% |
| 6 | ROIV Roivant Sciences Ltd. | Healthcare | 8.09M | $286.14M | 4.75% | -200.0K | -2.4% | Reduced | 1.12% |
| 7 | RLAY Relay Therapeutics, Inc. | Healthcare | 14.11M | $263.93M | 4.38% | +4.36M | +44.7% | Added | 6.45% |
| 8 | TVTX Travere Therapeutics, Inc. | Healthcare | 3.75M | $213.18M | 3.54% | -390.0K | -9.4% | Reduced | 3.98% |
| 9 | KARD Kardigan, Inc. | Healthcare | 8.20M | $195.59M | 3.25% | +8.20M | – | New | 8.77% |
| 10 | EWTX Edgewise Therapeutics, Inc. | Healthcare | 4.37M | $177.71M | 2.95% | -50.0K | -1.1% | Reduced | 4.06% |
| 11 | AMLX Amylyx Pharmaceuticals, Inc. | Healthcare | 8.33M | $149.69M | 2.49% | +50.0K | +0.6% | Added | 7.48% |
| 12 | MGTX MeiraGTx Holdings plc | Healthcare | 10.79M | $145.73M | 2.42% | +460.6K | +4.5% | Added | 11.45% |
| 13 | ORKA Oruka Therapeutics, Inc. | Healthcare | 1.35M | $128.01M | 2.13% | -50.4K | -3.6% | Reduced | 2.14% |
| 14 | INBX Inhibrx Biosciences, Inc. | Healthcare | 1.30M | $122.96M | 2.04% | -144.9K | -10.0% | Reduced | 8.28% |
| 15 | PTGX Protagonist Therapeutics, Inc | Healthcare | 981.9K | $120.36M | 2% | -249.0K | -20.2% | Reduced | 1.49% |
Tip. Select a row to see that position’s full history at Perceptive Advisors.
As of its Q2 2026 13F filing, Perceptive Advisors LLC’s five largest positions were Praxis Precision Medicines, Inc. (PRAX) at 11.3%, Spyre Therapeutics, Inc. (SYRE) at 6.4%, Celcuity Inc. (CELC) at 5.6%, Ascendis Pharma A/S (ASND) at 5.2%, Rhythm Pharmaceuticals, Inc. (RYTM) at 4.8% of the reported portfolio.
Perceptive Advisors LLC reported a 13F portfolio worth $6.02B across 92 positions for Q2 2026. That is up 35.2% from the previous quarter.
Its largest purchases by value were Kardigan, Inc. ($195.59M), Avalyn Pharma Inc. ($88.07M), Relay Therapeutics, Inc. ($81.48M). It opened 19 new positions.
Its largest sales by value were Ascendis Pharma A/S ($98.07M), Dyne Therapeutics, Inc. ($43.97M), Guardant Health, Inc. ($38.81M). It exited 7 positions entirely.
From the Form 13F-HR reports Perceptive Advisors LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.